Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2019
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited
Details : The portfolio to be divested to Teijin Pharma is comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Product Name : Liovel
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 26, 2021
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Lead Product(s) : Alogliptin Benzoate,Pioglitazone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Takeda Completes Sale of Four Diabetes Products in Japan to Teijin Pharma Limited
Details : The portfolio divested to Teijin Pharma was comprised of four non-core type 2 diabetes products (Nesina®, Liovel®, Inisync® and Zafatek®) sold in Japan, which generated total sales of approximately JPY 30.8 billion in FY2019.
Product Name : Liovel
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Alogliptin Benzoate,Pioglitazone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Teijin Pharma
Deal Size : $1,250.0 million
Deal Type : Divestment
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Celltrion
Deal Size : $278.0 million
Deal Type : Divestment
Takeda to Divest Select APAC Assets to Celltrion for $278M
Details : The portfolio to be divested to Celltrion includes a variety of OTC products and pharmaceutical products such as Nesina® and Edarbi® and Products in a variety of indications.
Product Name : Liovel
Product Type : Other Small Molecule
Upfront Cash : $266.0 million
November 06, 2020
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Celltrion
Deal Size : $278.0 million
Deal Type : Divestment
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 18, 2018
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 03, 2017
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 3 Alogliptin Pediatric Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2016
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Takeda Pharmaceutical | Kyung Hee University Hospital at Gangdong | Bucheon St. Mary's Hospital | Korea University Guro Hospital | Ajou University School of Medicine | Inha University | Kangbuk Samsung Hospital | Seoul Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2016
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Takeda Pharmaceutical | Kyung Hee University Hospital at Gangdong | Bucheon St. Mary's Hospital | Korea University Guro Hospital | Ajou University School of Medicine | Inha University | Kangbuk Samsung Hospital | Seoul Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
An Extension Study of PEAK Trial
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 05, 2016
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Takeda Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Bioavailability Study of SYR-322MET
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 24, 2015
Lead Product(s) : Alogliptin Benzoate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
